Murine model for non-invasive imaging to detect and monitor ovarian cancer recurrence

Journal of Visualized Experiments

Volumn , Issue 93, 2014, Pages

  Sumi, Natalia J ^a   Lima, Eydis ^a   Pizzonia, John ^b   Orton, Sean P ^c   Craveiro, Vinicius ^a   Joo, Wonduk ^a   Holmberg, Jennie C ^a   Gurrea, Marta ^a   Yang Hartwich, Yang ^a   Alvero, Ayesha ^a   Mor, Gil ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NatureMost Laboratories   (United States)

^c Bruker Preclinical Imaging   (United States)

Author keywords

Cancer biology; Cancer stem cells; Chemotherapy; In vivo imaging; Issue 93; Ovarian cancer; Recurrence; Tumor burden

Indexed keywords

ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; FEMALE; FLUORESCENCE IMAGING; HUMAN; MOUSE; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; TUMOR RECURRENCE; XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; MONITORING, PHYSIOLOGIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OPTICAL IMAGING; OVARIAN NEOPLASMS;

EID: 84911454259     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51815     Document Type: Article

References (23)

1. Cho, K. R. Ovarian cancer update: lessons from morphology, molecules, and mice. Archives of pathology & laboratory medicine. 133, 1775-1781 (2009).
2. Jong, M., Maina, T. Of mice and humans: are they the same?--Implications in cancer translational research. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 51, 501-504 (2010).
3. Langdon, S. P. Animal modeling of cancer pathology and studying tumor response to therapy. Current drug targets. 13, 1535-1547 (2012).
4. Mullany, L. K., Richards, J. S. Minireview: animal models and mechanisms of ovarian cancer development. Endocrinology. 153, 1585-1592 (2012).
5. Ricci, F., Broggini, M., Damia, G. Revisiting ovarian cancer preclinical models: implications for a better management of the disease. Cancer treatment reviews. 39, 561-568 (2013).
6. Pizzonia, J., et al. Multimodality animal rotation imaging system (Mars) for in vivo detection of intraperitoneal tumors. Am J Reprod Immunol. 67, 84-90 (2012).
7. House, C. D., Hernandez, L., Annunziata, C. M. Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer. Frontiers in oncology. 4, 26(2014).
8. Rao, J., Dragulescu-Andrasi, A., Yao, H. Fluorescence imaging in vivo: recent advances. Current opinion in biotechnology. 18, 17-25 (2007).
9. Manegold-Brauer, G., Bellin, A. K., Tercanli, S., Lapaire, O., Heinzelmann-Schwarz, V. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Archives of gynecology and obstetrics. 289, 491-498 (2014).
10. Zinn, K. R., et al. Noninvasive bioluminescence imaging in small animals. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 49, 103-115 (2008).
11. Rockall, A. G., et al. Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test-Retest Measurements for Tumor FDG Uptake, Diameter, and Volume. Clin Cancer Res. 20, 2751-2760 (2014).
12. Hickson, J. In vivo optical imaging: preclinical applications and considerations. Urologic oncology. 27, 295-297 (2009).
13. Contag, C. H., Bachmann, M. H. Advances in in vivo bioluminescence imaging of gene expression. Annual review of biomedical engineering. 4, 235-260 (2002).
14. Alvero, A. B., et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 8, 158-166 (2009).
15. Alvero, A. B., et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells.27, 2405-2413 (2009).
16. Alvero, A. B., et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer. (2009).
17. Chefetz, I., et al. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle. 12, 511-521 (2013).
18. Liu, M., et al. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci. 20, 605-615 (2013).
19. Steffensen, K. D., et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol. 2011, 620523(2011).
20. Craveiro, V., Yang-Hartwich, Y., Holmberg, J., Sumi, N., Pizzonia, J., Griffin, B., Gill, S., Silasi, D., Azodi, M., Rutherford, T., Alvero, A. B., Mor, G. Phenotypic Modifications in Ovarian Cancer Stem Cells Following Paclitaxel Treatment. Cancer Medicine. (2013).
21. Kuroda, H., Marino, M. P., Kutner, R. H., Reiser, J., et al. Production of lentiviral vectors in protein-free media. Current protocols in cell biology / editorial board, Juan S. Bonifacino..[etal.]. 26, (2011).
22. Yin, G., et al. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene. 32, 39-49 (2013).
23. Vassileva, V., Allen, C. J., Piquette-Miller, M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther. 7, 630-637 (2008).